This report offers an in-depth examination of Türkiye’s healthcare system, providing an overview of its structure and operations.
Key areas covered include:
- Drug Approval and Pricing:
An outline of Türkiye’s pharmaceutical regulatory framework, including marketing authorization pathways (standard, abridged, conditional, and exceptional licensing), how medicines and devices are approved, and the strict pricing environment based on international reference pricing and fixed exchange rates.
- Healthcare Access and Reimbursement:
An explanation of how patients access care in Türkiye’s universal health system, including reimbursement decisions led by the Social Security Institution (SGK), the role of Named Patient and Compassionate Use programs, and mechanisms like Managed Entry Agreements for innovative therapies.
- Procurement:
A review of how pharmaceuticals and medical supplies are procured within Türkiye’s decentralized public sector, primarily through hospital-level and regional tenders on the Electronic Public Procurement Platform (EKAP).
- Future Trends and Outlook:
Insights into Türkiye’s healthcare evolution, including the growth of digital health and telemedicine, expansion of medical tourism, major initiatives like the Turkish Genome Project, and efforts to strengthen the healthcare workforce and infrastructure for long-term sustainability.
